6 recruiting, 3 completed, 1 unknown. 4 Phase 2, 3 Not applicable, 3 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 3, Completed 1 |
| Not applicable | 3 | Recruiting 2, Completed 1 |
| Phase 1 | 3 | Recruiting 2, Unknown 1 |
| Phase 3 | 1 | Completed 1 |
Follow Locally Advanced Prostate Cancer: new trials by email Literature Review of Locally Advanced Prostate Cancer trials Research Report on Locally Advanced Prostate Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Addition of Focal Boost to Primary Radiotherapy for Prostate Cancer in 12 or 20 Fractions Addition of focal boost and hypofractionation - Prostate Cancer Patients Undergoing External Radiation and Seed Implantation, High Risk Localised Prostate Carcinoma | Not applicable | Recruiting | Copenhagen University Hospital, Rigshospitalet | 1016 | 2025-12-15 | 2026-01-21 |
| STereotActic Body Radiotherapy and 177Lutetium PSMA in Locally Advanced Prostate Cancer Lu-PSMA-617, 5-fraction Stereotactic Body Radiation Therapy (SBRT) - Malignant Neoplasm of Prostate, Locally Advanced Prostate Cancer | Phase 1 / Phase 2 | Recruiting | Angela Y. Jia, MD PhD | 45 | 2025-05-13 | 2026-05-26 |
| Relugolix + Enzalutamide Study in High-Risk Prostate Cancer Relugolix and Enzalutamide - Androgen Deprivation Therapy, Locally Advanced Prostate Cancer | Phase 1 | Recruiting | University of Oklahoma | 46 | 2024-12-26 | 2026-03-05 |
| Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) Rezvilutamide, Goserelin Microspheres for Injection, Docetaxel - Locally Advanced Prostate Cancer, Oligometastatic Prostate Cancer | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 40 | 2024-04-01 | 2024-04-26 |
| Improved Robotic-Assisted Radical Prostatectomy for Locally Advanced Prostate Cancer: Bladder Suspension and Preliminary Outcomes conventional Robotic-assisted radical prostatectomy group, Improved Robotic-assisted radical prostatectomy group - Robotic-Assisted Radical Prostatectomy, Locally Advanced Prostate Cancer | Not applicable | Recruiting | First Affiliated Hospital of Fujian Medical University | 300 | 2024-01-01 | 2025-05-18 |
| Effects of Triptorelin Pamoate 6-month When Given to Adult Chinese Participants With Advanced Cancer in the Prostate Triptorelin pamoate (embonate) salt - Advanced Prostate Cancer, Metastatic Prostate Cancer | Phase 3 | Completed | Ipsen | 195 | 2022-11-17 | 2025-09-09 |
| Neoadjuvant Intense Endocrine Therapy for High Risk and Locally Advanced Prostate Cancer ADT, Abiraterone Acetate, Prednisolone tablets - Neoadjuvant Therapy, High Risk Prostate Cancer | Phase 2 | Recruiting | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | 900 | 2020-02-01 | 2022-08-16 |
| MRI Guided Transurethral HIFU for Various Prostate Diseases MRI guided transurethral HIFU ablation of prostatic tissue - Localised Prostate Cancer, Locally Advanced Prostate Cancer | Not applicable | Completed | Turku University Hospital | 87 | 2017-07-24 | 2024-11-25 |
| Combination Casodex® and Iressa™ in Locally Advanced Prostate Cancer Iressa - Locally Advanced Prostate Cancer | Phase 2 | Completed | AstraZeneca | 102 | 2003-12-01 | 2011-01-25 |
| TNFerade Biologic to Treat Locally Advanced Prostate Cancer TNFerade™ Biologic - Locally Advanced Prostate Cancer | Phase 1 | Unknown | GenVec | 20 | 2012-03-12 |
Prostatic Neoplasms (4) · Neoplasm, Residual (1) · Pathologic Complete Response (1) · Prostatic Hyperplasia (1)
Neoplasms (5) · Genital Diseases (4) · Genital Diseases, Male (4) · Genital Neoplasms, Male (4) · Male Urogenital Diseases (4) · Neoplasms by Site (4) · Prostatic Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Disease Attributes (1) · Disease Progression (1) · Neoplastic Processes (1) · Pathologic Processes (1) · Pathological Conditions, Signs and Symptoms (1)
enzalutamide (2) · Abiraterone Acetate (1) · Cisplatin (1) · Docetaxel (1) · Gefitinib (1) · Injections (1) · Pluvicto (1) · Poly(ADP-ribose) Polymerase Inhibitors (1) · Prednisolone (1) · Salts (1) · TNFeraseBiologic (1) · Triptorelin Pamoate (1) · apalutamide (1) · pamiparib (1) · relugolix (1)
Angela Y. Jia, MD PhD (1) · AstraZeneca (1) · Copenhagen University Hospital, Rigshospitalet (1) · First Affiliated Hospital of Fujian Medical University (1) · GenVec (1) · Ipsen (1) · The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (1) · The First Affiliated Hospital of Xiamen University (1) · Turku University Hospital (1) · University of Oklahoma (1)
China (4) · United States (3) · Denmark (1) · Finland (1) · Norway (1)
Angela Y Jia, MD, PhD (1) · Daniel E Spratt, MD (1) · Kaiyan Zhang, M.D. (1)
PMID 31466481, PMID 32897169, PMID 36711157, PMID 40065286, PMID 42031503